Recombinant Human CD300e Fc Chimera Alexa Fluor® 647 Protein

Streptavidin coated beads conjugated to biotinylated anti-human CD300e/LMIR6 Monoclonal Antibody were stained with the indicated concentrations of Recombinant Human CD300e/LMIR6 Fc Chimera Alexa Fluor® 647 (Catalog # AFR10479).

2 μg/lane of Recombinant Human CD300e Fc Chimera Alexa Fluor® 647 Protein (Catalog # AFR10479) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 45-58 kDa and 106-125 kDa (non-reducible dimer), and 90-120 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity

Recombinant Human CD300e Fc Chimera Alexa Fluor® 647 Protein Summary

• Additional Information: LMIR6
• Details of Functionality: Measured by flow cytometry for its ability to bind anti-Human CD300e/LMIR6 Monoclonal Antibody conjugated beads.The concentration of Recombinant Human CD300e/LMIR6 Chimera Alexa Fluor® 647 (Catalog # AFR10479) that produces 50% of the binding response is 0.20‑4.00 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human CD300e/LMIR6 protein
  

  Human CD300e/LMIR6 (Leu18-Leu169) Accession # Q496F6.2	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q496F6.2
• N-terminal Sequence: Leu18
• Structure / Form: Disulfide-linked homodimer
  Labeled with Alexa Fluor® 647

  Excitation Wavelength: 650 nm

  Emission Wavelength: 668 nm
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 44 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 45-58 kDa and 106-125 kDa (non-reducible dimer), under reducing conditions.

Packaging, Storage & Formulations

• Storage: Protect from light. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CD300e Fc Chimera Alexa Fluor® 647 Protein

• CD300 antigen like family member E
• CD300 antigen-like family member E
• CD300e antigenPIgR-2
• CD300e molecule
• CD300e
• CD300LE
• CD300LEPIgR2
• CLM2
• CLM-2
• CLM2CMRF35-A5
• CMRF35A5
• CMRF35-like molecule 2
• Immune receptor expressed on myeloid cells 2
• IREM-2
• IREM2IREM-2
• LMIR6
• Poly-Ig receptor 2
• Polymeric immunoglobulin receptor 2

Background

CD300e, also known as LMIR6, IREM-2, and CMRF35-like 2 (CLM-2), is an approximately 35-kDa type I transmembrane glycoprotein in the LMIR family of immune regulatory proteins (1). It consists of a 156 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and an 11 aa cytoplasmic stub (2). The ECD contains an Ig-like V-type domain with a single disulfide bond and an N-linked glycosylation site. Within the ECD, human CD300e shares 57% sequence identity with mouse and rat CD300e. Its transmembrane segment contains a charged lysine residue which mediates CD300e association with the signaling adaptor molecule DAP12 and enables CD300e to function as an activating receptor (2, 3, 5). The ligand of CD300e is unknown; sphingomyelin has been demonstrated to bind human and mouse CD300e (5). CD300e is highly expressed on intermediate and non-classical monocytes, and myeloid dendritic cells (3, 4). CD300e on monocytes from HIV-infected patients under cART is correlated with markers of disease progression and immune inflammation (6). The cross-linking of CD300e enhances LPS-mediated cytokine production by monocytes, enhancing TNF-alpha production while no enhancement is observed on IL-1 beta , IL-6 and IL-10 (7). Our in-house data indicate that CD300e inhibits T cell activation, including anti-CD3-induced IL-2 and IFN-gamma secretion.

1. Clark, G.J. et al. (2009) Trends Immunol. 30:209.
2. Chung, D.H. et al. (2003) J. Immunol. 141:6541.
3. Aguilar, H. et al. (2004) J. Immunol. 173:6703.
4. Brckalo, T. et al. (2010) Eur. J. Immunol. 40:722.
5. Isobe, M. et al. (2018) J. Biol. Chem. 293:3793.
6. Vitalle, J. et al. (2017) Front. Immunol. 8:836.
7. Zenarruzabeitia O. et al. (2016) Sci Rep. 6:32693.

Bioinformatics

• Uniprot:
  • Q496F6.2()